BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2026 4:22:07 AM | Browse: 2 | Download: 99
 |
Received |
|
2025-10-29 14:00 |
|
Peer-Review Started |
|
2025-10-29 14:00 |
|
First Decision by Editorial Office Director |
|
2026-01-19 08:21 |
|
Return for Revision |
|
2026-01-19 08:21 |
|
Revised |
|
2026-02-02 15:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-25 02:34 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-25 10:06 |
|
Articles in Press |
|
2026-02-25 10:06 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-20 01:36 |
|
Publish the Manuscript Online |
|
2026-09-11 04:22 |
| ISSN |
2220-3192 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Abdul Basit, Muhammad Hamza Aslam, Muhammad Moneeb Anwar, Muhammad Ahmad Sarwar, Ammara Akram, Qamar Ismail, Abdullah Iftikhar and Majeed Haq |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Majeed Haq, Department of Pharmacology, Shaheed Suhrawardy Medical College and Hospital, Sher-E-Bangla Nagar, Dhaka 1207, Bangladesh. b0807621@gmail.com |
| Key Words |
Ticagrelor; Dual antiplatelet therapy; Percutaneous coronary intervention; P2Y12 inhibitors; Aspirin |
| Core Tip |
Ticagrelor monotherapy after short-term dual antiplatelet therapy significantly reduces bleeding without increasing ischemic risk in high-risk percutaneous coronary intervention patients. This meta-analysis of > 20000 patients supports aspirin discontinuation after 1-3 months of dual antiplatelet therapy. Findings reinforce evolving guidelines toward simplified, safer antiplatelet strategies post-percutaneous coronary intervention. |
| Publish Date |
2026-09-11 04:22 |
| Citation |
Basit A, Aslam MH, Anwar MM, Sarwar MA, Akram A, Ismail Q, Iftikhar A, Haq M. Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention. World J Pharmacol 2026; 15(2): 115880
|
| URL |
https://www.wjgnet.com/2220-3192/full/v15/i2/115880.htm |
| DOI |
https://doi.org/10.5497/wjp.115880 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
